1. China Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: other
Guangdong Zhongsheng Pharmaceutical Co., Ltd. Class A

Guangdong Zhongsheng Pharmaceutical Co., Ltd. Class A

SSZSE:002317
25.97
CNY
+0.02
(+0.08%)
0.27EPS
85.88P/E
20.88BMarket Cap
Oct 30Next Earn
Guangdong Zhongsheng Pharmaceutical Co., Ltd. Class A
SZSE:002317
(Shenzhen Stock Exchange)

Recent

price

25.97

P/E

ratio

85.88

div

yld

0.77%

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
CNY
0.89
1.05
1.22
1.51
1.81
2.18
2.25
2.43
2.93
3.11
2.36
3.06
3.32
3.17
2.97
3.02
2.72
Revenue per Share
0.18
0.21
0.25
0.26
0.31
0.41
0.55
0.52
0.54
0.39
-0.53
0.35
0.4
0.32
-0.36
0.33
0.29
Basic EPS, GAAP
0.01
-0.16
0.09
- -
-0.14
0.16
0.26
0.3
0.23
0.15
-0.02
0.52
-0.25
-0.21
0.13
-0.01
- -
Free Cash Flow per Basic Share
0.06
0.08
0.1
0.12
0.13
0.31
0.14
0.2
0.22
0.25
0.24
0.24
0.23
0.21
0.21
0.2
0.2
Dividend per Share
1.93
2.05
2.2
2.34
2.5
2.79
4.17
4.55
4.79
4.99
4.33
4.27
4.55
5.1
4.6
4.77
4.71
Book Value per Share
1.88
1.98
2.13
2.18
2.24
1.01
2.53
2.55
2.4
2.65
3.35
3.22
3.3
3.71
3.64
3.68
3.57
Tangible Book Value per Share
721
717
726
722
724
724
753
808
807
815
805
793
805
823
831
836
845
Basic Weighted Avg Shares
641
751
886
1,090
1,309
1,578
1,692
1,964
2,362
2,532
1,896
2,429
2,676
2,611
2,467
2,523
2,300
Sales/Revenue/Turnover
19.66
20.18
19.77
16.63
17.07
20.26
25.31
23.46
21.9
19.05
14.82
16.48
14.75
13.48
11.13
12.71
12.46
Operating Margin (%)
15
20
26
30
50
63
68
70
78
98
99
96
100
121
125
125
- -
Depreciation Expense
132
151
182
188
225
297
414
420
436
318
-427
278
322
263
-299
276
242
Net Income, GAAP
14.13
14.05
14.71
14.04
13
13.53
13.01
13.98
13.89
15.6
- -
11.25
14.38
11.9
- -
10.08
7.22
Effective Tax Rate (%)
20.53
20.05
20.48
17.22
17.16
18.81
24.48
21.39
18.45
12.55
-22.5
11.43
12.03
10.08
-12.12
10.93
10.52
Profit Margin (%)
1,182
1,107
1,212
1,136
1,098
120
1,448
1,376
1,506
1,627
2,312
2,147
2,126
2,945
2,259
2,325
2,399
Working Capital
- -
- -
- -
6
- -
- -
- -
- -
348
235
232
313
290
98
- -
6
5
LT Debt
1,387
1,477
1,587
1,743
1,899
2,110
3,424
3,730
3,951
4,134
3,626
3,538
3,816
4,526
4,010
4,150
4,091
Total Equity
9.05
10.07
11.05
10.63
11.14
13.41
13.78
10.98
9.57
6.57
- -
6.63
7.28
5.26
- -
5.77
5.19
Return on Invested Capital (%)
9.71
10.54
11.87
11.22
12.7
14.41
14.31
11.06
10.5
7.26
- -
8.24
8.93
6.38
- -
6.21
5.83
Return on Capital (%)
9.81
10.51
11.85
11.48
12.71
15.18
15.19
11.83
11.45
7.97
-11.24
7.93
8.97
6.53
-7.23
6.92
6.05
Return on Common Equity (%)

Capital Structure

CNY

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
320
290
119
LT Borrowings
- -
- -
- -
LT Finance Leases
6
6
5
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
850
850
850
Market Capitalization
16,132
15,639
20,883

Working Capital

CNY

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
3,044
3,431
3,021
Cash, Cash Equivalents & STI
1,089
1,127
1,191
Accounts Receivable, Net
573
565
488
Inventories
365
354
386
Total Current Liabilities
718
830
622
Payables & Accruals
- -
- -
- -
ST Debt
320
290
119
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
8.56%
3.22%
3.48%
Free Cash Flow
-325.39%
-635.57%
-110.01%
Net Income, GAAP
-78.97%
-114.63%
-192.18%
Sales/Revenue/Turnover
5.83%
6.52%
2.24%
Total Cash Common Dividend
1.16%
-2.75%
-0.38%

Quarterly Revenue

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
641
723
544
559
2,467
2025
634
665
- -
634
2,523
2026
624
376
- -
- -
- -

Quarterly Earnings Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.06
0.04
0.08
-0.53
-0.36
2025
0.1
0.12
- -
0.03
0.33
2026
0.12
0.01
- -
- -
- -

Quarterly Dividends Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
0.2
- -
- -
0.21
2025
- -
- -
- -
- -
0.2
2026
- -
0.2
- -
- -
- -
Similar Companies
Cipla Ltd (NSE:CIPLA)
Aurobindo Pharma Ltd (NSE:AUROPHARMA)
Lupin Limited (NSE:LUPIN)
Granules India Limited (NSE:GRANULES)
Revolution Medicines, Inc. (NASDAQ:RVMD)
Egyptian International Pharmaceutical Industries Co. (EGX:PHAR)
Business
Guangdong Zhongsheng Pharmaceutical Co., Ltd. researches, develops, produces and sells pharmaceutical products principally in China with a focus on ophthalmology, cardiovascular, cerebrovascular, respiratory, digestive, diabetes, tumor and senile degenerative diseases; the company offers Chinese patent medicines including compound thrombotron series products, brain embolization capsules, compound salvia tablets, zongsheng pills series products and heat-clearing and dehumidifying granules, as well as chemical medicines such as liritvir tablets, onradivir tablets, cefixime dispersible tablets, cefradine capsules, ribavirin tablets, rifampicin capsules, azelastine hydrochloride eye drops, cyclosporine eye drops and loratadine tablets. Founded in 1979 and headquartered in Dongguan, Guangdong Province at the Information Industry Park in Shilong Town's Xihu Industrial Zone, the company operates ten subsidiaries and four major production bases targeting hospitals, retail pharmacies and healthcare facilities primarily in China with over 85% of sales from the domestic market. In 2024, the company reported revenue of 2.47 billion yuan, a 5.5% year-on-year decline amid asset impairment provisions of 550 million yuan including goodwill impairments for subsidiaries Xianqiang Pharmaceutical and Yishu Pharmaceutical and R&D project write-downs for items such as ZSP1602 and ZSP1241; it recently extended guarantees up to 2 billion yuan for subsidiaries including Zhongsheng Medical Trade and Yikang Pharmaceutical to support operations and financing with banks like China Bank and CMB.